stockrow
Friday 6 November 2026
Export QDEL’s income statement to Excel — free account
QuidelOrtho Corporation
QDEL Healthcare Medical Devices
QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024.
- Revenue
- −11.6%
- EPS
- +92.7%
- Free cash flow
- +120.7%
- Total debt
- +10.5%
Quarter to September 2026, against a year earlier
10.73
2.11
−16.43%
Follow QDEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.71 | 0.42 | 0.45 | 0.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
14.68 | (33.96) | (10.82) | 36.94 | |
P/B ratio |
1.01 | 0.61 | 0.67 | 0.41 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.62 | 1.38 | 1.48 | 1.35 | |
EV/EBITDA |
19.76 | 22.24 | 11.79 | 10.39 | |
EV/Operating CF |
41.98 | 555.78 | (69.31) | 442.40 | |
EV/FCF |
(52.95) | (22.95) | (18.73) | (29.54) | |
Quick Ratio |
0.61 | 0.52 | 0.48 | 0.51 | |
Current Ratio |
1.50 | 1.43 | 1.39 | 1.36 | |
Net Debt/EBITDA |
53.69 | 31.41 | 24.69 | 0.00 | |
Debt/Assets |
45.94% | 47.76% | 50.59% | 50.81% | |
Debt/Equity |
1.38 | 1.45 | 1.63 | 1.64 | |
Asset Turnover |
0.45 | 0.44 | 0.44 | 0.45 | |
Operating CF/Net income |
(1.01) | 0.36 | 1.19 | (0.36) | |
Capex/Depreciation |
(0.40) | (0.30) | (0.19) | 0.00 | |
Interest Coverage |
(1.30) | (0.62) | (0.40) | (0.14) | |
Research and Development Expense of Revenue |
6.33% | 7.24% | 7.72% | 6.87% | |
Selling, General and Administrative Expense of Revenue |
26.87% | 32.16% | 30.07% | 29.52% | |
Intangible Assets out of Total Assets |
0.44 | 0.45 | 0.47 | 0.45 | |
Share Based Compensation of Revenue |
1.49% | 1.73% | 1.90% | 0.00% | |
Graham Net Nets |
(1.24) | (2.14) | (2.14) | (3.51) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(58.33%) | (108.46%) | (87.96%) | (51.36%) | |
Free Cash Flow Yield |
(4.31%) | (14.26%) | (17.68%) | (16.34%) | |
Revenue per Share |
10.67 | 9.09 | 9.24 | 9.01 | |
Operating CF per Share |
1.95 | (0.48) | (1.62) | 0.29 | |
Capex per Share |
(0.67) | (0.50) | (0.37) | 0.00 | |
Free Cash Flow per Share |
1.28 | (0.98) | (1.99) | 0.29 | |
Cash per Share |
2.50 | 2.06 | 1.81 | 2.42 | |
Shareholders Equity per Share |
28.33 | 27.15 | 25.99 | 26.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.33 | 27.15 | 25.99 | 26.07 | |
Free Cash Flow |
86.60 | (67.00) | (136.10) | 19.60 | |
Working Capital |
481.20 | 414.60 | 383.20 | 378.90 | |
Capital Expenditures |
(45.30) | (34.00) | (25.50) | (21.00) | |
Net Current Asset Value |
(2,401.50) | (2,400.30) | (2,563.80) | (2,544.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.05 | 0.04 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
349.70 | 322.95 | 313.50 | 381.00 | |
Average Payables |
262.70 | 237.20 | 227.65 | 233.50 | |
Average Inventory |
555.65 | 587.35 | 598.80 | 628.25 | |
Average Assets |
6,096.45 | 6,045.15 | 6,047.20 | 5,728.20 | |
Average Common Equity |
2,452.50 | 2,424.30 | 2,283.80 | 1,913.85 |
Columns are period end dates · fundamentals updated 5 Nov 2026